{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:21:04Z","timestamp":1787822464426,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-026-03034-w","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:26:52Z","timestamp":1787581612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Increased LDL-C reduction with ezetimibe in ketogenic diet-induced hypercholesterolemia"],"prefix":"10.1186","volume":"25","author":[{"given":"Jorge","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Wageman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tro","family":"Kalayjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Calkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Saner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9173-7440","authenticated-orcid":false,"given":"Adrian","family":"Soto-Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"3034_CR1","doi-asserted-by":"publisher","first-page":"nzab144","DOI":"10.1093\/cdn\/nzab144","volume":"6","author":"NG Norwitz","year":"2021","unstructured":"Norwitz NG, Feldman D, Soto-Mota A, Kalayjian T, Ludwig DS. Elevated LDL cholesterol with a carbohydrate-restricted diet: evidence for a lean mass hyper-responder phenotype. Curr Dev Nutr. 2021;6:nzab144.","journal-title":"Curr Dev Nutr"},{"key":"3034_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/metabo14010073","volume":"14","author":"NG Norwitz","year":"2024","unstructured":"Norwitz NG, Cromwell WC. Oreo cookie treatment lowers LDL cholesterol more than high-intensity statin therapy in a lean mass hyper-responder on a ketogenic diet: a curious crossover experiment. Metabolites. 2024;14:73.","journal-title":"Metabolites"},{"key":"3034_CR3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ajcnut.2024.01.009","volume":"119","author":"A Soto-Mota","year":"2024","unstructured":"Soto-Mota A, Flores-Jurado Y, Norwitz NG, Feldman D, Pereira MA, et al. Increased low-density lipoprotein cholesterol on a low-carbohydrate diet in adults with normal but not high body weight: a meta-analysis. Am J Clin Nutr. 2024;119:740\u20137.","journal-title":"Am J Clin Nutr"},{"key":"3034_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3390\/metabo12050460","volume":"12","author":"NG Norwitz","year":"2022","unstructured":"Norwitz NG, Soto-Mota A, Kaplan B, Ludwig DS, Budoff M, et al. The Lipid Energy Model: reimagining lipoprotein function in the context of carbohydrate-restricted diets. Metabolites. 2022;12:460.","journal-title":"Metabolites"},{"key":"3034_CR5","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","volume":"265","author":"A Pandor","year":"2009","unstructured":"Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009;265:568\u201380.","journal-title":"J Intern Med"},{"key":"3034_CR6","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1161\/01.CIR.0000143163.76212.0B","volume":"110","author":"P Parini","year":"2004","unstructured":"Parini P, Davis M, Lada AT, Erickson SK, Wright TL, et al. ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. Circulation. 2004;110:2017\u201323.","journal-title":"Circulation"},{"key":"3034_CR7","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/S0022-2275(20)42269-2","volume":"31","author":"KM Cianflone","year":"1990","unstructured":"Cianflone KM, Yasruel Z, Rodriguez MA, Vas D, Sniderman AD. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J Lipid Res. 1990;31:2045\u201355.","journal-title":"J Lipid Res"},{"key":"3034_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fnins.2019.00005","volume":"13","author":"I D\u2019Andrea Meira","year":"2019","unstructured":"D\u2019Andrea Meira I, Rom\u00e3o TT, Pires do Prado HJ, Kr\u00fcger LT, Pires MEP, et al. Ketogenic diet and epilepsy: what we know so far. Front Neurosci. 2019;13:5.","journal-title":"Front Neurosci"},{"key":"3034_CR9","doi-asserted-by":"publisher","first-page":"1489812","DOI":"10.3389\/fnut.2024.1489812","volume":"11","author":"A Kiryttopoulos","year":"2025","unstructured":"Kiryttopoulos A, Evangeliou AE, Katsanika I, Boukovinas I, Foroglou N, et al. Successful application of dietary ketogenic metabolic therapy in patients with glioblastoma: a clinical study. Front Nutr. 2025;11:1489812.","journal-title":"Front Nutr"},{"key":"3034_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s13300-018-0373-9","volume":"9","author":"SJ Hallberg","year":"2018","unstructured":"Hallberg SJ, McKenzie AL, Williams PT, Bhanpuri NH, Peters AL, et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, non-randomized, controlled study. Diabetes Ther. 2018;9:583\u2013612.","journal-title":"Diabetes Ther"},{"key":"3034_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12933-018-0698-8","volume":"17","author":"NH Bhanpuri","year":"2018","unstructured":"Bhanpuri NH, Hallberg SJ, Williams PT, McKenzie AL, Ballard KD, et al. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open-label, non-randomized, controlled study. Cardiovasc Diabetol. 2018;17:56.","journal-title":"Cardiovasc Diabetol"},{"key":"3034_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4102\/JMH.v7i1.100","volume":"7","author":"T Kalayjian","year":"2024","unstructured":"Kalayjian T, McNally B, Calkins M, Cucuzzella M, Cywes R, et al. The SMHP\u2122 position statement on therapeutic carbohydrate reduction for type 1 diabetes. J Metab Health. 2024;7:1.","journal-title":"J Metab Health"},{"key":"3034_CR13","doi-asserted-by":"publisher","first-page":"1548609","DOI":"10.3389\/fnut.2025.1548609","volume":"12","author":"L Buchanan","year":"2025","unstructured":"Buchanan L, Calkins M, Kalayjian T, Norwitz NG, Teicholz N, et al. TOWARD, a metabolic health intervention, demonstrates robust 1-year weight loss and cost-savings through deprescription. Front Nutr. 2025;12:1548609.","journal-title":"Front Nutr"},{"key":"3034_CR14","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/metabo12090848","volume":"12","author":"NG Norwitz","year":"2022","unstructured":"Norwitz NG, Soto-Mota A, Kalayjian T. A company is only as healthy as its workers: a 6-month metabolic health management pilot program improves employee health and contributes to cost savings. Metabolites. 2022;12:848.","journal-title":"Metabolites"},{"key":"3034_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/MED.0000000000000566","volume":"27","author":"S Das","year":"2020","unstructured":"Das S, McCreary J, Shamim S, Kalayjian T. Reversal of severe hypertriglyceridemia with intermittent fasting and a very-low-carbohydrate ketogenic diet: a case series. Curr Opin Endocrinol Diabetes Obes. 2020;27:308\u201311.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"3034_CR16","doi-asserted-by":"publisher","first-page":"1394610","DOI":"10.3389\/fnut.2024.1394610","volume":"11","author":"DM Diamond","year":"2024","unstructured":"Diamond DM, Mason P, Bikman BT. Opinion: are mental health benefits of the ketogenic diet accompanied by an increased risk of cardiovascular disease? Front Nutr. 2024;11:1394610.","journal-title":"Front Nutr"},{"key":"3034_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jamapsychiatry.2025.4431","volume":"83","author":"M Gao","year":"2026","unstructured":"Gao M, Kirk M, Knight H, Lash E, Michalopoulou M, et al. A ketogenic diet for treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2026;83:331\u201340.","journal-title":"JAMA Psychiatry"},{"key":"3034_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamapsychiatry.2025.3261","volume":"83","author":"R Janssen-Aguilar","year":"2026","unstructured":"Janssen-Aguilar R, Vije T, Peera M, Al-Shamali HF, Meshkat S, et al. Ketogenic diets and depression and anxiety: a systematic review and meta-analysis. JAMA Psychiatry. 2026;83:13\u201322.","journal-title":"JAMA Psychiatry"},{"key":"3034_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40337-020-0278-7","volume":"8","author":"M Carmen","year":"2020","unstructured":"Carmen M, Safer DL, Saslow LR, Kalayjian T, Mason AE, et al. Treating binge eating and food addiction symptoms with low-carbohydrate ketogenic diets: a case series. J Eat Disord. 2020;8:2.","journal-title":"J Eat Disord"},{"key":"3034_CR20","doi-asserted-by":"publisher","first-page":"1612551","DOI":"10.3389\/fpsyt.2025.1612551","volume":"16","author":"E Saner","year":"2025","unstructured":"Saner E, Kalayjian T, Buchanan L, Calkins M, Soto-Mota A, et al. TOWARD: a metabolic health intervention that improves food addiction and binge eating symptoms. Front Psychiatry. 2025;16:1612551.","journal-title":"Front Psychiatry"},{"key":"3034_CR21","doi-asserted-by":"publisher","first-page":"1005523","DOI":"10.3389\/fpsyt.2022.1005523","volume":"13","author":"J Unwin","year":"2022","unstructured":"Unwin J, Delon C, Gi\u00e6ver H, Kennedy C, Painschab M, et al. Low carbohydrate and psychoeducational programs show promise for the treatment of ultra-processed food addiction. Front Psychiatry. 2022;13:1005523.","journal-title":"Front Psychiatry"},{"key":"3034_CR22","doi-asserted-by":"publisher","first-page":"951376","DOI":"10.3389\/fpsyt.2022.951376","volume":"13","author":"A Danan","year":"2022","unstructured":"Danan A, Westman EC, Saslow LR, Ede G. The ketogenic diet for refractory mental illness: a retrospective analysis of 31 inpatients. Front Psychiatry. 2022;13:951376.","journal-title":"Front Psychiatry"},{"key":"3034_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41392-021-00549-9","volume":"6","author":"C Kong","year":"2021","unstructured":"Kong C, Yan X, Liu Y, Huang L, Zhu Y, et al. Ketogenic diet alleviates colitis by reduction of colonic group 3 innate lymphoid cells through altering gut microbiome. Signal Transduct Target Ther. 2021;6:154.","journal-title":"Signal Transduct Target Ther"},{"key":"3034_CR24","doi-asserted-by":"publisher","first-page":"1467475","DOI":"10.3389\/fnut.2024.1467475","volume":"11","author":"NG Norwitz","year":"2024","unstructured":"Norwitz NG, Soto-Mota A. Case report: carnivore-ketogenic diet for the treatment of inflammatory bowel disease: a case series of 10 patients. Front Nutr. 2024;11:1467475.","journal-title":"Front Nutr"},{"key":"3034_CR25","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S0002-9149(02)02798-4","volume":"90","author":"CA Dujovne","year":"2002","unstructured":"Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092\u20137.","journal-title":"Am J Cardiol"},{"key":"3034_CR26","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","volume":"107","author":"CM Ballantyne","year":"2003","unstructured":"Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409\u201315.","journal-title":"Circulation"},{"key":"3034_CR27","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.clinthera.2004.11.016","volume":"26","author":"HE Bays","year":"2004","unstructured":"Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe\/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2004;26:1758\u201373.","journal-title":"Clin Ther"},{"key":"3034_CR28","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.120.045373","volume":"145","author":"I Semova","year":"2022","unstructured":"Semova I, Levenson A, Krawczyk J, Bullock K, Gearing M, et al. Insulin prevents hypercholesterolemia by suppressing 12\u03b1-hydroxylated bile acids. Circulation. 2022;145:969\u201382.","journal-title":"Circulation"},{"key":"3034_CR29","doi-asserted-by":"publisher","first-page":"879355","DOI":"10.3389\/fcvm.2022.879355","volume":"9","author":"X Xiao","year":"2022","unstructured":"Xiao X, Luo Y, Peng D. Updated understanding of the crosstalk between glucose\/insulin and cholesterol metabolism. Front Cardiovasc Med. 2022;9:879355.","journal-title":"Front Cardiovasc Med"},{"key":"3034_CR30","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1161\/ATVBAHA.113.301517","volume":"33","author":"AD Sniderman","year":"2013","unstructured":"Sniderman AD, Qi Y, Ma CI, Wang RH, Naples M, et al. Hepatic cholesterol homeostasis: is the low-density lipoprotein pathway a regulatory or a shunt pathway? Arterioscler. Thromb Vasc Biol. 2013;33:2481\u201390.","journal-title":"Thromb Vasc Biol"},{"key":"3034_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.7555\/JBR.31.20160139","volume":"31","author":"R Scott Kiss","year":"2017","unstructured":"Scott Kiss R, Sniderman A. Shunts, channels and lipoprotein endosomal traffic: a new model of cholesterol homeostasis in the hepatocyte. J Biomed Res. 2017;31:95\u2013107.","journal-title":"J Biomed Res"},{"key":"3034_CR32","volume-title":"Introduction to lipids and lipoproteins","author":"KR Feingold","year":"2000","unstructured":"Feingold KR. In: Feingold E, Adler KR, Ahmed RA, editors. Introduction to lipids and lipoproteins. South Dartmouth: S. F. et al.) (MDText.com, Inc.; 2000. Updated 14 Jan 2024."},{"key":"3034_CR33","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/CIRCULATIONAHA.122.058883","volume":"145","author":"V Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s V, Eckel RH. Insulin and bile acids in cholesterol homeostasis: new players in diabetes-associated atherosclerosis. Circulation. 2022;145:983\u20136.","journal-title":"Circulation"},{"key":"3034_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00125-003-1261-y","volume":"47","author":"VW Bloks","year":"2004","unstructured":"Bloks VW, Bakker-van Waarde WM, Verkade HJ, Kema IP, Wolters H, et al. Down-regulation of hepatic and intestinal Abcg5 and Abcg8 expression associated with altered sterol fluxes in rats with streptozotocin-induced diabetes. Diabetologia. 2004;47:104\u201312.","journal-title":"Diabetologia"},{"key":"3034_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11745-002-0875-5","volume":"37","author":"M Igel","year":"2002","unstructured":"Igel M, Lindenthal B, Giesa U, von Bergmann K. Evidence that leptin contributes to intestinal cholesterol absorption in obese (ob\/ob) mice and wild-type mice. Lipids. 2002;37:153\u20137.","journal-title":"Lipids"},{"key":"3034_CR36","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1053\/j.gastro.2008.01.032","volume":"134","author":"C G\u00e4lman","year":"2008","unstructured":"G\u00e4lman C, Bonde Y, Matasconi M, Angelin B, Rudling M. Dramatically increased intestinal absorption of cholesterol following hypophysectomy is normalized by thyroid hormone. Gastroenterology. 2008;134:1127\u201336.","journal-title":"Gastroenterology"},{"key":"3034_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1089\/met.2014.0114","volume":"13","author":"K Ciriacks","year":"2015","unstructured":"Ciriacks K, Coly G, Krishnaswami S, Patel SB, Kidambi S. Treatment of hyperlipidemia in patients with type 1 diabetes mellitus: a brief review of the available evidence with focus on ezetimibe. Metab Syndr Relat Disord. 2015;13:84\u201390.","journal-title":"Metab Syndr Relat Disord"},{"key":"3034_CR38","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","volume":"105","author":"C Gagn\u00e9","year":"2002","unstructured":"Gagn\u00e9 C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469\u201375.","journal-title":"Circulation"},{"key":"3034_CR39","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","volume":"358","author":"JJP Kastelein","year":"2008","unstructured":"Kastelein JJP, Akdim F, Stroes ESG, Zwinderman AH, Bots ML, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431\u201343.","journal-title":"N Engl J Med"},{"key":"3034_CR40","doi-asserted-by":"crossref","unstructured":"Mansfield BS, Dello-Iacono A, Raal FJ. Ezetimibe in the management of homozygous familial hypercholesterolaemia. J Clin Lipidol. 2025;19(2):320\u20136. Epub 2024 Nov 15.","DOI":"10.1016\/j.jacl.2024.11.003"},{"key":"3034_CR41","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamacardio.2020.6184","volume":"6","author":"DP Marcus","year":"2021","unstructured":"Marcus DP, Giugliano RP, Park JG, de Lemos JA, Cannon CP, et al. Association of baseline low-density lipoprotein cholesterol and percentage low-density lipoprotein cholesterol reduction with statins, ezetimibe, and PCSK9 inhibition. JAMA Cardiol. 2021;6:582\u20136.","journal-title":"JAMA Cardiol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-026-03034-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-03034-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-03034-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:52:54Z","timestamp":1787820774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12944-026-03034-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3034"],"URL":"https:\/\/doi.org\/10.1186\/s12944-026-03034-w","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was as IRB-exempt by the Wake Forest University Health Sciences- Wake Forest School of Medicine, Wake Forest University Institutional Review Board, with the reference code IRB00137763, and with a waiver of informed consent granted due to the retrospective nature of the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors reviewed and approved the final manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joshua Wageman is an employee of Amgen Inc. The other authors declare no competinginterests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"187"}}